AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Peripheral Blood Stem Cell TransplantationTransplantation, AutologousHematopoietic Stem Cell TransplantationMultiple MyelomaHematopoietic Stem Cell MobilizationMelphalanTransplantation ConditioningTransplantation, HomologousGranulocyte Colony-Stimulating FactorCombined Modality TherapyLeukapheresisAntigens, CD34Hematologic NeoplasmsBlood Component RemovalStem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideMyeloablative AgonistsTreatment OutcomeBusulfanGraft vs Host DiseaseLymphoma, Non-HodgkinRemission InductionBone Marrow TransplantationGraft SurvivalAntineoplastic Agents, AlkylatingHematopoietic Stem CellsEtoposideRecurrenceThiotepaSalvage TherapyVincristineCarmustineCytophagocytosisDisease-Free SurvivalIfosfamideAmyloidosisBoronic AcidsPyrazinesThalidomideSurvival RateRetrospective StudiesStem CellsCytarabineDexamethasoneHematopoiesisHodgkin DiseaseCord Blood Stem Cell TransplantationPrednisoneTransplantation ChimeraSurvival AnalysisDoxorubicinNeoplasmsTissue DonorsTime FactorsWhole-Body IrradiationInfectionLymphoma, T-CellAntineoplastic AgentsPOEMS SyndromePlatelet CountHistocompatibilityBone MarrowHistocompatibility TestingFollow-Up StudiesCarboplatinImmunosuppressive AgentsLeukemia, Myeloid, AcuteBone Marrow PurgingTransplantation, IsogeneicVidarabinePlasma CellsBlood Cell CountRecombinant ProteinsLeukemiaLymphomaImmunophenotypingPrognosisProspective StudiesFatal OutcomeBlood CellsCytomegalovirus InfectionsGraft vs Leukemia EffectFeasibility StudiesMyeloma ProteinsMyelodysplastic SyndromesFlow CytometryAnemia, AplasticParaproteinemiasBlood Transfusion, AutologousLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLiver TransplantationLymphocyte DepletionBone Marrow CellsLeukocytes, MononuclearT-LymphocytesHematologic DiseasesOpportunistic InfectionsHistiocytosis, Non-Langerhans-CellLivedo Reticularis
HSCTTransplantBoneASCTMelphalanMarrowGraft-versus-RelapseTransplantsAmyloidosisLeukemiaTreatment of multiple myelomaDexamethasoneInternational Myeloma WorkshopImmunoTherapyTumorsRefractoryPlasma Cell My2023Post-autologousPatient'sNewly diagnosedAcuteGranulocyte-colonyHigh-dose cyclophosphamideCancerLymphomasHodgkin'sOutcomesCyclophosphamideBortezomibRequires the patient to undergoProgenitor cellsRenal cell carcPreviously untreatedMyeloablative2019SurvivalMonoclonalVitroSymptomaticLenalidomideMalignant plasma cellsKidney transplantationClinicalDoseTumor cellsAntigenMETHODSRegimen
HSCT22
  • Hematopoietic stem cell transplantation (HSCT) is a broad term that covers the transplantation of blood progenitor/stem cells from any source. (drugdiscoverynews.com)
  • Among the conditions HSCT can treat are: acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma, non-Hodgkin lymphoma, Hodgkin disease, aplastic anemia and pure red-cell aplasia-but this list is not exhaustive. (drugdiscoverynews.com)
  • Other groups are also working on cell therapies for the treatment of poor graft function after HSCT. (drugdiscoverynews.com)
  • Their ongoing Phase 2 study is evaluating whether infusion of mesenchymal stem cells (MSCs) can treat steroid-resistant acute graft-versus-host disease (GVHD) or poor graft function after HSCT. (drugdiscoverynews.com)
  • GVHD, which is common among allogenic HSCT and rare in autologous HSCT, can be acute or chronic. (drugdiscoverynews.com)
  • An essential component of allogeneic and autologous hematopoietic stem cell transplantation (HSCT) is the conditioning regimen administered before the hematopoietic cell infusion. (org.in)
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • In order to better understand the LPI kinetics and its determinants and implications, we undertook sequential LPI determinations before and after conditioning until engraftment in 25 auto-HSCT patients. (karger.com)
  • His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
  • One needs to differentiate between tandem transplants, a planned sequence of two high dose treatments with HSCT salvage, and a second transplant, an approach of consolidating the first autologous HSCT with another HSCT ONLY if the first one appears partially effective. (cancertreatmenttoday.org)
  • In this report, we summarize the case of a patient with MM status post autologous HSCT and chronic kidney disease who experienced worsening hypertension along with a substantial increase in proteinuria shortly after the initiation of carfilzomib for the treatment of refractory disease. (biomedcentral.com)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • Data were collected between March and September of 2016, through the evaluation of the medical records of 43 patients who underwent HSCT and developed some type of psychological distress. (bvsalud.org)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
  • Since then, allogeneic hematopoietic stem cell transplantation (HSCT) has evolved to become a frequently used and effective therapy for many hematologic malignancies. (longdom.org)
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
Transplant53
  • 05). Life-threatening cardiac toxicity was not significantly increased in patients with pathologic results before transplant. (slideshare.net)
  • A total of 179 transplant-eligible patients with newly diagnosed MM treated at a single academic center were included. (biomedcentral.com)
  • Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. (nature.com)
  • Transplant Cell Ther. (bu.edu)
  • Remissions may be brought about with steroids, chemotherapy, targeted therapy, and stem cell transplant. (wikipedia.org)
  • 1 Significant advances have been made by combining novel agents with autologous peripheral blood stem cell transplantation which allows for long-term disease-free survival in the majority of transplant-eligible patients. (haematologica.org)
  • We report a case of disseminated microsporidiosis in a patient with multiple myeloma who had received an allogeneic stem cell transplant requiring substantial immunosuppression. (cdc.gov)
  • in an immunosuppressed patient who received an allogeneic stem cell transplant for multiple myeloma. (cdc.gov)
  • After receiving an autologous stem cell transplant (SCT), she experienced a relapse of disease and was enrolled in an experimental protocol of immunoablative chemotherapy, followed by hematopoietic SCT at the National Institutes of Health Clinical Center in Bethesda, Maryland ( www.ClinicalTrials.gov identifier NCT00520130). (cdc.gov)
  • The bone marrow did not reconstitute, and 35 days after the initial transplant, the patient received a second SCT from the same donor after a conditioning regimen with antithymocyte globulin. (cdc.gov)
  • Microsporidium detected in clinical specimens from a stem cell transplant patient who had undergone substantial immunosuppression. (cdc.gov)
  • this should lead to better overall survival in both transplant and non-transplant patients. (medscape.com)
  • Stem cell therapy, or stem cell transplant, is a procedure that aims to restore blood-forming stem cells in patients who have undergone chemotherapy or radiotherapy . (parkwaycancercentre.com)
  • Autologous stem cell (patient's own stem cells) transplant is used to help patients recover from the effects of chemotherapy. (parkwaycancercentre.com)
  • Allogeneic stem cell (stem cells from a donor) transplant is used to help patients recover from the effects of chemotherapy and/or radiotherapy as well as to eradicate the remaining cancer cells in the patient after chemotherapy and/or radiotherapy. (parkwaycancercentre.com)
  • Stem cell transplant is often a part of the treatment plan for blood cancers. (parkwaycancercentre.com)
  • In allogeneic stem cell (stem cells from a donor) transplant, there is another benefit in addition to replenishing the HSCs in the bone marrow after chemotherapy or radiotherapy. (parkwaycancercentre.com)
  • The stem cells originate from the patient who will receive the transplant. (parkwaycancercentre.com)
  • A donor, either related or unrelated to the patient, who donates the stem cells for transplant. (parkwaycancercentre.com)
  • Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. (astct.org)
  • This trial confirmed the results of other trials that demonstrated a substantial incidence of symptomatic hypotension in MM patients in the peri-transplant period following ASCT. (astct.org)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • Building off experience in hematopoietic stem cell transplant and exploiting advances in genetic engineering, genome editing, immunology, immunotherapy, stem cell biology, understanding disease mechanisms and cell therapy manufacturing, considerable progress has been made with hundreds of clinical trials underway. (bdbiosciences.com)
  • In this type of transplant, the patient's own stem cells are collected before the high-dose chemotherapy and/or radiation therapy is given. (vanyahealth.com)
  • This type of transplant is used when the patient's own cells are not damaged or diseased, but are being used as a rescue therapy after high-dose chemotherapy or radiation therapy. (vanyahealth.com)
  • In this type of transplant, stem cells are taken from a donor (usually a close relative or sibling) and given to the patient. (vanyahealth.com)
  • This type of transplant is used when the patient's own cells are damaged or diseased. (vanyahealth.com)
  • The donor's cells are not as well matched to the patient's cells as in a standard allogeneic transplant, which increases the risk of complications such as graft-versus-host disease (GVHD) and graft rejection. (vanyahealth.com)
  • Cord blood transplant is a type of allogeneic transplant that uses stem cells from the umbilical cord of a newborn baby. (vanyahealth.com)
  • The main advantage is that cord blood cells are less mature than adult stem cells, which makes it less likely for the patient's immune system to reject the transplant. (vanyahealth.com)
  • However, cord blood units often have fewer stem cells than a bone marrow or peripheral blood transplant, which can increase the time it takes for the patient's blood counts to recover. (vanyahealth.com)
  • Both haploidentical BMT and cord blood transplant are considered alternative options for patients who do not have a suitable matched donor. (vanyahealth.com)
  • This occurs when the donated cells attack the patient's own cells in case of allogeneic transplant. (vanyahealth.com)
  • Patients who have had a bone marrow transplant are at an increased risk of infections due to the suppression of their immune system. (vanyahealth.com)
  • Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
  • A tandem autologous transplant, also known as a double autologous transplant, requires the patient to undergo two planned autologous stem cell transplants within 6 months. (cancertreatmenttoday.org)
  • Stem cells are collected once before the initial transplant and half are used for each procedure. (cancertreatmenttoday.org)
  • On the other hand, for patients who have not responded completely, NCCN recommends second transplant. (cancertreatmenttoday.org)
  • After stem cell collection, EDAP (etoposide, dexamethasone, cytarabine, cisplatin) was given to enhance reduction of tumor cells prior to high-dose therapy (melphalan 200 mg/m²) and autologous transplant. (cancertreatmenttoday.org)
  • In addition, it has yet to be determined which patients benefit most from a tandem transplant. (cancertreatmenttoday.org)
  • The issue of allogeneic after autologous transplant is reviewed under a separate heading. (cancertreatmenttoday.org)
  • After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. (biomedcentral.com)
  • Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. (biomedcentral.com)
  • In this context, patients experience the first psychological conflicts before this transplant. (bvsalud.org)
Bone58
ASCT14
  • The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT). (biomedcentral.com)
  • Peripheral blood samples were collected for measuring monocytic (M-) MDSCs (CD14 pos HLA-DR low/neg ) and early-stage (E-) MDSCs (Lin neg HLA-DR neg CD33 pos CD11b pos ) before and after ASCT. (biomedcentral.com)
  • Both MDSC phenotypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. (biomedcentral.com)
  • We propose that targeting CSF1R on these cells may improve the results of ASCT in MM. (biomedcentral.com)
  • The occurrence of varicella zoster virus (VZV) reactivation is increased after allogeneic transplantation, whereas limited data are available for herpes zoster (HZ) after autologous SCT (ASCT). (nature.com)
  • We determined the incidence and the prognostic significance of HZ and its correlation with VZV serology in 191 consecutive myeloma patients undergoing high-dose melphalan chemotherapy with ASCT. (nature.com)
  • We found that VZV reactivation occurred in 57 (30%) patients, in 8.5% during induction and in 21.5% after ASCT peaking at 8 months after ASCT. (nature.com)
  • By immune fluorescence and Serion Elisa VZV IgG assessment, 90.8% of all patients had specific anti-VZV antibodies at ASCT. (nature.com)
  • Lower specific antibody titers at transplantation were observed in patients with HZ after ASCT than in those without reactivation ( P =0.009). (nature.com)
  • Finally, OS was better in myeloma patients with HZ after ASCT compared with patients without HZ ( P =0.007). (nature.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. (smw.ch)
  • Current choices for first-line treatment of systemic L-chain amyloidosis are autologous stem cell transplantation (ASCT) and combination chemotherapy (see Treatment and Medication ). (medscape.com)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
Melphalan9
Marrow13
  • Biology of Blood and Marrow Transplantation , 25 (7), 1312-1319. (elsevierpure.com)
  • In patients treated with Plerixafor in combination with G-CSF for HSC mobilization, tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. (fresenius-kabi.com)
  • Atkinson K, Meyers J, Storb R, Prentice RL, Thomas ED . Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. (nature.com)
  • Infection with varicella-zoster virus after marrow transplantation. (nature.com)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). (shengsci.com)
  • CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival. (shengsci.com)
  • Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine p. (rochester.edu)
  • Marrow biopsy was consistent with IgG myeloma. (doctorsmedicalopinion.com)
  • However, the yellow marrow can revert to red if there is increased demand for red blood cells, such as in instances of blood loss. (medscape.com)
  • Normally, only mature cells are released from the marrow into the bloodstream. (medscape.com)
  • These stem cells divide to eventually give rise to red blood cells, platelets, and most white blood cells in the red marrow. (medscape.com)
Graft-versus-3
  • Patients in this study are given a conditioning regimen of chemotherapy drugs (including fludarabine and cyclophosphamide), followed by prophylaxis against graft-versus-host disease (alemtuzumab and cyclosporine). (cdc.gov)
  • Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. (uchicago.edu)
  • Solid tumors, autoimmune diseases, graft versus host disease (GvHD), genetic diseases and neurodegenerative diseases are investigated using many types of autologous and allogeneic cells with rapidly evolving cell engineering and editing approaches. (bdbiosciences.com)
Relapse7
  • Despite these clinical improvements, the vast majority of patients eventually experience disease relapse and progression. (biomedcentral.com)
  • A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma. (fredhutch.org)
  • Background Patients with gene expression profiling-defined high-risk myeloma in relapse have poor outcomes with current therapies. (haematologica.org)
  • Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
  • Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. (nwbio.com)
Transplants6
  • Additionally, stem cell transplants can also be categorised based on who donates the stem cells. (parkwaycancercentre.com)
  • BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (uchicago.edu)
  • Cord blood transplants are an alternative to using stem cells from a matched adult donor. (vanyahealth.com)
  • Preliminary results of several randomized trials comparing tandem and single autologous transplants, which have not been followed as long, have also shown superior event-free survival with the tandem regimen in most studies. (cancertreatmenttoday.org)
  • It appears that in patients with poor prognostic features, outcome is not improved with tandem transplants, so additional strategies need to be evaluated in this patient population. (cancertreatmenttoday.org)
  • A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. (biomedcentral.com)
Amyloidosis5
Leukemia19
  • His pioneering work spans discoveries in basic biology of blood stem cells and leukemia to first-in-human clinical trials for people with cancer and heart diseases, alongside shaping innovative policies in state health and healthcare financing. (ufl.edu)
  • Therefore, Plerixafor is not intended for HSC mobilization and harvest in patients with leukemia. (fresenius-kabi.com)
  • microsporidian myositis was recently reported in a patient with chronic lymphocytic leukemia ( 1 ). (cdc.gov)
  • [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • A systematic review by He et al demonstrated a reduction in vertebral compressions and time to progression with early systemic treatment for asymptomatic patients, but this study also revealed an increase in acute leukemia in the early treatment group. (medscape.com)
  • FDA approved quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (org.in)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • Several patients with clinical features of chronic myeloid leukemia (CML) have fusion of the TEL (ETV6) gene on 12p13 with ABL on 9q34 and express a chimeric Tel-Abl protein that contains the same portion of the Abl tyrosine kinase fused to Tel, an Ets family transcription factor, rather than Bcr. (shengsci.com)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
  • Autologous T cells genetically modified to express CARs targeting the B-cell antigen B-lymphocyte antigen CD19 (CD19) have caused complete remissions in a small number of patients with leukemia or lymphoma. (survivornet.com)
  • Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. (uchicago.edu)
  • Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. (uchicago.edu)
  • Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. (uchicago.edu)
  • CAR-T cells, which incorporate an antibody-derived extracellular receptor and T cell derived intracellular signaling domains, have shown convincing outcomes in certain types of leukemia and lymphoma, including commercial licensure of CD19 CAR-Ts for the treatment of relapsed/ refractory large B cell lymphoma and acute lymphoblastic leukemia. (bdbiosciences.com)
  • The technique has also shown preliminarily promising outcomes in B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma and multiple myeloma in clinical trials targeting CD19, CD20, CD22, CD30 and B-cell maturation antigen (BCMA), with many more under investigation. (bdbiosciences.com)
  • This procedure is typically used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma, as well as other disorders such as sickle cell anemia and thalassemia. (vanyahealth.com)
  • Poláková Katarína, Železníková Tatiana, Russ Gustáv: HLA-G5 in the blood of leukemia patients and healthy individuals. (sav.sk)
Treatment of multiple myeloma1
Dexamethasone3
International Myeloma Workshop1
  • The 2009 International Myeloma Workshop concluded that detection of any cytogenic abnormality suggests higher-risk disease, including chromosomal 13 or 13q deletion, t(4;14), and del17p and fluorescence in situ hybridization detection of t(4;14), t(14;16), and del17p. (medscape.com)
ImmunoTherapy2
  • Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. (nwbio.com)
  • Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. (nwbio.com)
Tumors5
  • Adoptive transfer of expanded natural killer cells inhibited the growth of established OPM2 and high-risk primary myeloma tumors grown in the murine model. (haematologica.org)
  • Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors. (cancernetwork.com)
  • In this regard, clinical research focused on the effect of the profile of immune system is performed among patients with hematologic malignancies and those with solid tumors. (cancerdiagnosisprognosis.org)
  • We have constructed a novel anti-BCMA CAR that can specifically recognize BCMA- expressing target cells in vitro and eradicate BCMA-expressing tumors in mice. (survivornet.com)
  • Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. (nwbio.com)
Refractory14
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • FDA granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (org.in)
  • FDA granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (org.in)
  • FDA granted accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. (org.in)
  • FDA granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (org.in)
  • the efficacy of the combination therapy is well demonstrated by large-scale studies, regardless of initial therapy or refractory/relapsed status ( N Engl J Med 372(2) (2015)">16 - Blood 131(3) (2018)">22 ). (cancerdiagnosisprognosis.org)
  • Conclusion Daratumumab was safe and effective in inducing remission in two patients with severe treatment-refractory AAV, warranting prospective clinical trials to establish safety and efficacy. (bmj.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. (nwbio.com)
  • A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. (biomedcentral.com)
  • We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma. (biomedcentral.com)
  • Bortezomib is a proteasome inhibitor that was approved by the Food and Drug Administration (FDA) in 2003 for the treatment of refractory MM and subsequently in 2008 as an initial treatment of patients with MM. Although it does not target VEGF directly, bortezomib has also been reported to be associated with TMA. (biomedcentral.com)
Plasma Cell My1
  • Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. (wikipedia.org)
20231
  • Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase, Blood Advances, Vol.7, No.6, 1019-1032, 2023. (matci.jp)
Post-autologous1
Patient's3
  • After the chemotherapy and radiation therapy, the stored stem cells are thawed and returned to the patient's body. (vanyahealth.com)
  • The donor's cells are a genetic match to the patient's, which reduces the risk of rejection. (vanyahealth.com)
  • They come with their own set of risks and benefits, and the decision to use them will depend on the patient's specific circumstances and the availability of a suitable cord blood unit or haploidentical donor. (vanyahealth.com)
Newly diagnosed2
  • While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. (biomedcentral.com)
  • Up to 80% of patients with newly diagnosed multiple myeloma. (org.in)
Acute3
  • For example, absolute lymphocyte counts (ALCs), a simple laboratory parameter that is routinely evaluated in the clinical setting, has been found to be associated with treatment outcomes in patients with diffuse large B cell lymphoma, follicular lymphoma, or acute leukemias ( Am J Hematol 84(2) (2009)">1 - Br J Haematol 134(6) (2006)">3 ). (cancerdiagnosisprognosis.org)
  • The second patient with proteinase 3-ANCA-positive granulomatosis with polyangiitis, diffuse alveolar haemorrhage necessitating extracorporeal membrane oxygenation (ECMO) and acute kidney failure, requiring kidney replacement therapy, was weaned off ECMO, mechanical ventilation and dialysis and discharged home after daratumumab. (bmj.com)
  • The recommended starting dose of bivalirudin for medically managed patients with acute coronary syndrome (ACS) is an intravenous bolus of 0.1 mg/kg followed by an infusion of 0.25 mg/kg/h. (medthority.com)
Granulocyte-colony3
  • Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma and is the newest addition to the company's generic injectable oncology medicine portfolio, the largest in U.S. health care. (fresenius-kabi.com)
  • Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). (fresenius-kabi.com)
  • The current treatment for incomplete hematopoietic recovery includes administration of factors stimulating white and red blood cell growth, such as granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin. (drugdiscoverynews.com)
High-dose cyclophosphamide2
Cancer25
  • In his early career Dr. Cogle discovered that blood stem cells make blood vessels and used that biology to invent new therapeutics and diagnostics for people with cancer and heart disease. (ufl.edu)
  • The introduction of this generic equivalent will provide patients and clinicians with access to more choices for their cancer care. (fresenius-kabi.com)
  • Large numbers of myeloid-derived suppressor cells (MDSCs), a mixture of monocytic and granulocytic cells, accumulate during many pathologic conditions, including cancer, infectious diseases, trauma, and sepsis. (biomedcentral.com)
  • Blood Cancer Journal 2016 May 13;6:e422. (fredhutch.org)
  • The present invention provides stem cells enriched with healthy functional mitochondria, and therapeutic methods utilizing such cells for the alleviation of debilitating conditions, including aging, and age-related diseases as well as the debilitating effects of anti-cancer therapies in subjects in need thereof. (justia.com)
  • The present invention relates to stem cells enriched with functional mitochondria, and therapeutic methods utilizing such cells to diminish the debilitating effects of various conditions, including aging and age-related diseases as well as the debilitating effects of anti-cancer therapy treatments. (justia.com)
  • 3] IPSS is explicitly used by clinical guidelines such as those published by the National Comprehensive Cancer Network (NCCN) to help inform the choice of therapy for MDS patients. (org.in)
  • There is a need for further investigation into the effects of and guidelines for exercise interventions (especially strength training) in this population of patients, particularly among cancer patients who are undergoing or have undergone chemotherapy or radiation treatments. (karger.com)
  • Mitka M: New oversight put in place for physicians giving anemia drugs to patients with cancer. (karger.com)
  • Courneya KS, Jones LW, Peddle CJ, Sellar CM, Reiman T, Joy AA, Chua N, Tkachuk L, Mackey JR: Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial. (karger.com)
  • Dimeo FC, Tilmann MH, Bertz H, Kanz L, Mertelsmann R, Keul J: Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. (karger.com)
  • Dolan LB, Gelmon K, Courneya KS, Mackey JR, Segal RJ, Lane K, Reid RD, McKenzie DC: Hemoglobin and aerobic fitness changes with supervised exercise training in breast cancer patients receiving chemotherapy. (karger.com)
  • If approved, UGN-102 may become the first non-surgical option for patients with low-grade intermediate-risk non-muscle invasive bladder cancer, says Sandip Prasad, MD. (cancernetwork.com)
  • The patient first receives a high dose of chemotherapy and/ or radiotherapy to eliminate the remaining cancer cells in the body. (parkwaycancercentre.com)
  • The donor immune cells can kill the leftover cancer cells and will exert a "graft-versus-cancer" effect, keeping the cancer cells in check. (parkwaycancercentre.com)
  • These cells can self-renew and the patient can enjoy a long-term cure from blood cancer. (parkwaycancercentre.com)
  • When a patient is diagnosed with a blood cancer or chronic blood condition, it is often the start of a new journey that will be the beginning of great change. (rochester.edu)
  • increased number of NK cells (particularly mature NK cells), helper T cells, and depleted Tregs can positively affect clinical outcomes ( Cancer Biomark 24(4) (2019)">4 - Leuk Res 66 (2018)">10 ). (cancerdiagnosisprognosis.org)
  • Multiple myeloma is a cancer of the blood plasma cells. (survivornet.com)
  • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. (nwbio.com)
  • Professor Ma heads the Blood, Stem Cell and Cancer Research Programme at St Vincent's Centre for Applied Medical Research, Sydney. (edu.au)
  • His biopsy showed left lower lobe lung mass that was a TTF-1 Non small cell lung cancer- most likely an adenocarcinoma. (doctorsmedicalopinion.com)
  • Chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. (cancertreatmenttoday.org)
  • Kučerová Lucia, Školeková Svetlana, Matúšková Miroslava, Bohac Martin, Kozovská Zuzana: Altered features and increased chemosensitivity of human breast cancer cells mediated by adipose tissue-derived mesenchymal stromal cells. (sav.sk)
  • Zvarik Milan, Martinický Dávid, Hunáková Ľubica, Šikurová Libuša: Fluorescence characteristics of human urine from normal individuals and ovarian cancer patients. (sav.sk)
Lymphomas2
  • Pretargeted Radioimmunotherapy for B-cell Lymphomas. (fredhutch.org)
  • Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
Hodgkin's1
  • The actuarial event-free survival for these 56 patients at 3 years was 37% and was at least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. (shengsci.com)
Outcomes2
  • Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK, Fay J. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. (nwbio.com)
Cyclophosphamide2
  • FDA approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. (org.in)
  • Methods We treated two patients with severe life-threatening AAV with renal and pulmonary manifestation despite induction therapy with rituximab and cyclophosphamide with four to eight doses of 1800 mg daratumumab. (bmj.com)
Bortezomib4
  • In phase I, doses of bortezomib (.7, 1.0, and 1.3 mg/m 2 ) with BuMel were administered to groups of 3 patients each. (elsevierpure.com)
  • These findings demonstrate that bortezomib is safe and has a potential role in conditioning regimens in combination with BuMel for patients with transplantation-eligible MM. (elsevierpure.com)
  • [ 34 ] A study by Neben et al concludes that long-term administration of bortezomib in patients with del(17p13) may result in better overall and progression-free survival. (medscape.com)
  • In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient. (biomedcentral.com)
Requires the patient to undergo1
  • Incomplete engraftment (poor graft function) requires the patient to undergo more transfusions of red cells or platelets. (drugdiscoverynews.com)
Progenitor cells1
  • Vasilyev Stanislav, Kubeš Miroslav, Marková Eva, Belyaev Igor: DNA damage response in CD133 + stem/progenitor cells from umbilical cord blood: Low level of endogenous foci and high recruitment of 53BP1. (sav.sk)
Renal cell carc3
  • Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. (uchicago.edu)
  • Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. (nwbio.com)
  • Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Völler MC, De Weijer K, Mulders PF, Oosterwijk E. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. (nwbio.com)
Previously untreated1
  • The final analysis of the landmark French IFM-94 trial demonstrated that double transplantation led to improved survival compared with single transplantation in patients with previously untreated myeloma. (cancertreatmenttoday.org)
Myeloablative1
  • Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
20191
Survival3
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • [ 32 ] The failure to demonstrate improved survival may be due to the small number of patients studied. (medscape.com)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
Monoclonal8
  • Of patients producing either IgG or IgA, 40% also have Bence Jones proteinuria, which is free monoclonal kappa ( κ ) or lambda ( λ ) light chains in the urine. (merckmanuals.com)
  • Rarely, patients have no M-protein in blood and urine, although the currently used serum free light chain assay now demonstrates monoclonal light chains in many of these formerly so-called nonsecretory patients. (merckmanuals.com)
  • 211At conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. (fredhutch.org)
  • These monoclonal plasma cell disorders can be categorized according to the total body burden of monoclonal plasma cells. (medscape.com)
  • In most patients with a monoclonal plasma cell disorder, whether multiple myeloma or MGUS, the monoclonal L chain secreted by the clone remains soluble in the bloodstream. (medscape.com)
  • Patients with this form are described as having nonamyloid monoclonal immunoglobulin deposition disease (MIDD). (medscape.com)
  • Multiple myeloma may develop from monoclonal gammopathy of undetermined significance (MGUS) that progresses to smoldering myeloma. (wikipedia.org)
  • T cell-targeted immunomodulators such as monoclonal antibodies against PD-1 or CTLA4 may be used in combination with CAR-T cells in clinical trials. (bdbiosciences.com)
Vitro2
  • We tested whether natural killer cells expanded by co-culture with K562 cells transfected with 41BBL and membrane-bound interleukin-15 could kill myeloma cells with a high-risk gene expression profile in vitro and in a unique model which recapitulates human myeloma. (haematologica.org)
  • IMiDs are known to enhance the immune system by NK cell expansion and activation, regulatory T cell (Treg) inhibition, and/or restoration of T cell function in in vitro studies ( J Mol Med (Berl) 94(12) (2016)">13 - Blood Rev 24(Suppl 1) (2010)">15 ). (cancerdiagnosisprognosis.org)
Symptomatic4
  • A total of 110 patients (64%) developed OH during the course of admission with 29% having symptomatic OH. (astct.org)
  • The main problem has been the symptomatic anemia, which required blood transfusions. (doctorsmedicalopinion.com)
  • Two hundred thirty-one patients with symptomatic myeloma were enrolled in Total Therapy I between 1990 and 1995 (Barlogie et al. (cancertreatmenttoday.org)
  • Treatment of thrombopathy requires, first of all symptomatic measures: haemostatic glues, desmopressin and the blood transfusion which must be only reserved for the difficult gestures or for the high hemorrhagic risk. (longdom.org)
Lenalidomide4
  • In a phase III trial that was restricted to patients with high-risk SMM, the PETHEMA group found evidence of benefit from treatment with lenalidomide versus observation. (medscape.com)
  • 2] Standard for describing populations of patients participating in pivotal clinical trials for MDS, including those that led to the approval of lenalidomide, azacitidine, and decitabine in most countries around the world. (org.in)
  • Conclusion: Immunomodulation by lenalidomide may improve prognosis in patients with RRMM. (cancerdiagnosisprognosis.org)
  • Although lenalidomide is considered to exert dual antitumor effects, including the activation of normal immune system through the activation of cytotoxic lymphocytes and the proteasome-dependent degradation of transcription factors such as IKZF1 and IKZF3 in myeloma cells ( J Mol Med (Berl) 94(12) (2016)">13 - Blood Rev 24(Suppl 1) (2010)">15 ), there is no clinical evidence that directly proves the association between changes in the profile of immune system and treatment efficacy in patients with MM treated with this agent. (cancerdiagnosisprognosis.org)
Malignant plasma cells1
Kidney transplantation2
Clinical6
  • Patients were treated within the randomized phase III clinical trials GMMG-HD6 (NCT02495922, 24/06/2015) and GMMG-HD7 (NCT03617731, 24/07/2018). (biomedcentral.com)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • To support evidence-based clinical guidelines on erythropoietin use for anemia in oncology, we conducted systematic reviews of controlled trials on four patient groups. (cancernetwork.com)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
  • Clinical improvement was paralleled by a strong reduction in serum ANCA levels as well as total IgG, indicating depletion of plasma cells. (bmj.com)
  • We look forward to other payers recognizing the clinical benefits of lumbar TDR enabling patients to maintain spinal motion and avoid adjacent segment disease. (ukpropertyguides.com)
Dose6
  • The presence of inflammatory cytokines after high-dose chemotherapy leads to proliferation and activation of MDSCs originating from autologous hematopoietic progenitors at the time of engraftment. (biomedcentral.com)
  • Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue. (nature.com)
  • The recommended dose of bivalirudin for patients undergoing PCI is an intravenous bolus of 0.75 mg/kg body weight followed immediately by an intravenous infusion at a rate of 1.75 mg/kg body weight/hour for at least the duration of the procedure. (medthority.com)
  • In STEMI patients the infusion of 1.75 mg/kg body weight/hour should be continued for up to 4 hours post-PCI and continued at a reduced dose of 0.25 mg/kg body weight/hour for an additional 4 - 12 hours as clinically necessary (see section 4.4). (medthority.com)
  • The bolus dose should be administered by a rapid intravenous push to ensure that the entire bolus reaches the patient before the start of the procedure. (medthority.com)
  • The infusion dose should be initiated immediately after the bolus dose is administered, ensuring delivery to the patient prior to the procedure, and continued uninterrupted for the duration of the procedure. (medthority.com)
Tumor cells3
  • The effect of potential reinfusion of tumor cells has not been well-studied. (fresenius-kabi.com)
  • Researchers hope the changed T cells will be better at recognizing and killing tumor cells. (survivornet.com)
  • Patient PBMCs are collected by leukapheresis followed by enrichment approaches to isolate T cells while removing other cells such as B cells, monocytes, neutrophils, dendritic cells and contaminating tumor cells. (bdbiosciences.com)
Antigen6
  • Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (merckmanuals.com)
  • Many factors dictate whether the donor stem cells are suitable for the recipient but the most important one is the human leukocyte antigen (HLA) system. (parkwaycancercentre.com)
  • Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. (shengsci.com)
  • T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens. (survivornet.com)
  • Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. (nwbio.com)
  • Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. (nwbio.com)
METHODS4
  • METHODS: We retrospectively examined the patient backgrounds, hemostatic results, and procedural safety in patients who were treated with a hemostatic peptide solution for hemostasis during emergency endoscopies for gastrointestinal bleeding. (bvsalud.org)
  • WO 2013/002880 describes compositions and methods comprising bio-energetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures. (justia.com)
  • US 20130022666 provides compositions comprising a lipid carrier and mitochondria as well as methods of delivering exogenous mitochondria to a cell and methods of treating or reversing progression of a disorder associated with mitochondrial dysfunction in a mammalian subject in need thereof. (justia.com)
  • Patients and Methods: In total, 72 patients with RRMM were treated with Ld. (cancerdiagnosisprognosis.org)
Regimen1
  • All patients except two who received reduced intensity had severe mucositis.Reversible veno-occlusive disease of the liver also developed in two patients.There was one death from graft-vs-host disease and no regimen-related mortality.Engraftment was prompt, with a median recovery of absolute neutrophil count to ³ 500/µL of 12 days (range: 11-18 days). (cancernetwork.com)